Introduction
Histone acetylation is a reversible event involved in transcriptional regulation. Indeed, acetylation of histone lysine tails provides a mechanism of regulation of gene expression via recruitment of components of the transcriptional machinery to specific DNA sites (Davie, 1997) . This mechanism is deregulated in many neoplasms, human leukaemias in particular, where its alteration constitutes a common shared leukaemogenic pathway (Look, 1997) . Core-binding factor (CBF) acute myeloid leukaemia (AML) exhibit gene rearrangements which involve genes encoding CBF subunits, such as AML1 (CBFa2) or CBFb. In particular, the translocation t(8;21; q22;q22), which leads to gene repression via the formation of the AML1/ETO chimaeric gene, may represent a paradigm for a molecular mechanism of leukaemogenesis (Downing, 1999) . In contrast to AML1, which recruits the transcriptional co-activators p300 and CBP endowed with intrinsic histone acetyl transferases (HAT) activity, AML1/ETO recruits, via NCoR/Sin3A, the histone deacetylase 1 (HDAC1), which drives the transcriptional repression of AML1-controlled genes (Ogawa et al., 1993; Ogryzko et al., 1996; Gelmetti et al., 1998; Kitabayashi et al., 1998; Wang et al., 1998) . Indeed, the AML1/ETO-centered multiprotein complex induces and stabilizes the local DNA methylation pattern by recruiting DNA methyltransferase-1 (DNMT1), resulting in the stable silencing of AML1-controlled genes, like those driving granulocytic maturation (Klisovic et al., 2003; Liu et al., 2005) . Similar DNA-binding repressor complexes are formed in the inv(16)-positive CBF-AML, PML/RARa-positive PML, as well as bcl6-positive lymphomas and account for epigenetic alterations critical to the development of malignant phenotype (Alcalay et al., 2001; Mrozek et al., 2001; Pasqualucci et al., 2003) .
Many efforts are directed to tailor de-repressive 'epigenetic' therapy to specific cancer subtypes by synthesizing different HDAC inhibitors (HDACi) for clinical use. In cancer cells, HDACi treatment can lead to transcriptional activation of about 2% of human genes, cell cycle arrest, maturation and apoptosis. HDACi are of potential interest, selectively acting as single drugs in neoplasms where HDAC are directly involved in oncogenesis, such as the above-mentioned CBF-AML, PML/RARa-positive PML and bcl6-positive lymphomas.
Hydroxamate derivatives are the most powerful category of HDACi, active on class I and II HDAC, especially on HDAC1 and HDAC2. In the study reported here, we described the anti-leukaemic properties of ITF2357, a recently synthesized, orally active hydroxamate derivative. Previous reports demonstrated that ITF2357 has HDAC inhibitory and anti-inflammatory properties in vitro and in vivo by blocking cytokines such as TNFa, IL1b, IL12 and so on (Leoni et al., 2005; Carta et al., 2006) . Furthermore, ITF2357 inhibits proliferation and markedly induces downregulation of antiapoptotic, and upregulation of proapoptotic, factors, in parallel with restoring histone acetylation in tumour cells (Armeanu et al., 2005; Pathil et al., 2006) . Clinical trials are currently being conducted with oral ITF2357 preparations in autoimmune disorders as well as haematological neoplasias.
We provide here evidence that AML1/ETO-positive AML cells are more sensitive than AML1/ETO-negative cells to low doses of ITF2357.
Results

Effects of ITF2357 on histone acetylation
Histone acetylation was assessed in AML1/ETO-positive Kasumi-1 cells after exposure to increasing doses of ITF2357 ( Figure 1a ). Cells were treated with ITF2357 0.01-5 mM for 6 h. The acetylation of histones H4 and H3, extremely weak in untreated Kasumi-1 cells (Gozzini et al., 2003) progressively increased in function of the ITF2357 dose, peaking at 0.5-1 mM. The dose of 0.1 mM, effective on both H3 and H4 acetylation, was selected to evaluate the kinetics of ITF2357 treatment (Figure 1b ). H4 and H3 acetylation peaked after a 1 h exposure to the drug and remained stable for 6 h, to decrease thereafter, although remaining above basal level at least up to 96 h. The amount of H4 was not altered by ITF2357 treatment.
As the effect of ITF2357 on histone acetylation appeared transient, we evaluated whether a repeated administration of the drug could modify the kinetics of its effect. Therefore, Kasumi-1 cultures were supplemented with 0.1 mM ITF2357 every 24 h, after a thorough cell washing directed to avoid possible additive effects of residual amounts of drug (Figure 1c ). Under these conditions, H4 acetylation resulted strongly increased after 24 h and remained stable at least up to 96 h.
Effects of ITF2357 on cell number and viability
We then deepened the characterization of the biological effects of ITF2357 on Kasumi-1 cells. In untreated control and 0.01 mM ITF2357-treated Kasumi-1 cultures, the number of viable cells increased significantly with respect to time zero after 48-72 h of incubation (Figure 2a) . Treatment with 0.1 mM ITF2357 completely suppressed this increase, while higher concentrations strongly reduced viable cell number with respect to time zero, with no cells surviving after 72 h of culture. The IC 50 value, as calculated at 48 h, was 0.2 mM. We then determined whether this reduction of cell number was paralleled by induction of apoptosis (Figure 2b ). Kasumi-1 cells, after 24 h of incubation in the absence of treatment, showed 20% basal apoptosis, as determined by the annexin V assay, in keeping with previous observations (Gozzini et al., 2003) . Exposure to 0.1 mM ITF2357 significantly increased the percentage of apoptotic cells, but maximal apoptosis values (up to 80-85%) where reached at 1 mM ITF2357. Repeated administrations of 0.1 mM ITF2357 (Figure 2c) , like in the experiments of Figure 1c , determined, at either 48 or 72 h, a significantly higher apoptosis than single administration. The time-course of caspase activation in response to 0.1 mM ITF2357 is shown in Figure 2d . Cleaved caspase 9 appeared after 6 h of treatment, while cleaved caspase 8 appeared after 72 h. Cleavage of caspase 3 appeared after 72 h and peaked at 96 h. Interestingly, AML1/ETO protein faded off in parallel (Figure 2d ), apparently due to caspase-dependent degradation, as revealed by AML1/ETO protein maintenance after a 96 h ITF2357 treatment in the presence of the pan-caspase inhibitor z-VAD-fmk but not Bortezomib (Figure 2e ). The Selectivity of low-dose ITF2357 in AML subtypes V Barbetti et al activity of z-VAD-fmk and Bortezomib was assessed in the same experiment (not shown). Heat shock protein 90 (Hsp90) is a chaperone protein known to stabilize AML1/ ETO (Yang et al., 2007) . As evidenced in Figure 2f , ITF2357 0.1 mM did not induce Hsp90 acetylation, as already shown (Carta et al., 2006) . Therefore, we may conclude that the ITF2357-dependent degradation of the fusion protein did not involve inactivation of Hsp90.
When suberanoyl hydroxamic acid (SAHA), the best characterized and the only FDA approved hydroxamate derivative, was used at 0.1 mM, H4 and H3 acetylation increased with a similar kinetics, but reduced efficacy compared to that of ITF2357 (Figure 3a) . Furthermore, SAHA, at this concentration, did not determine a decrease of viable cell number (Figure 3b ) or an increased percentage of apoptotic cells (Figure 3c ) with respect to Selectivity of low-dose ITF2357 in AML subtypes V Barbetti et al the untreated controls, so that higher concentrations of SAHA were needed to achieve significant effects on cell proliferation and apoptosis. In fact, the SAHA IC 50 value, as calculated at 48 h, was 0.8 mM.
Effects of ITF2357 on AML1/ETO-negative AML cells HDACi have been described as general inducers of maturation and inhibitors of cell proliferation in several types of neoplastic cells, leukaemic in particular. Our previous observations (Gozzini et al., 2003) indicated that CBF-positive leukaemias, t(8;21) in particular, are selectively sensitive to HDACi as for apoptosis and cell proliferation. For this reason, we tested the effects of ITF2357 on three AML1/ETO-negative AML cell lines: HL60, THP1 and PML/RARa-positive NB4, the latter representing another example of HDAC-involving leukaemogenesis. Acetylation of H4 and H3 was evaluated after a 6 h treatment with 0.1 or 1 mM ITF2357 ( Figure 4a ). All the cell lines responded to treatment with an increase of H4 and H3 acetylation, 1 mM Selectivity of low-dose ITF2357 in AML subtypes V Barbetti et al ITF2357 showing stronger effects than 0.1 mM. In NB4 cells, ATRA 1 mM did not induce significant histone acetylation, neither modified ITF2357-induced acetylation, at this time point. Treatment of HL60 cells for 48 h with 1 mM ITF2357 reduced viable cell number to zero, while 0.1 mM slightly reduced cell growth occurring in untreated cultures (Figure 4b) . IC 50 values, as calculated after 48 h treatment with ITF2357 or SAHA (graph not reported), were 0.3 and 1 mM, respectively. The growth of THP1 cells was reduced by 50% with respect to time zero by 1 mM ITF2357, but was not affected by 0.1 mM. IC 50 values, as calculated after 48 h treatment with ITF2357 or SAHA (graph not reported), were 0.4 and 1 mM, respectively. The growth of NB4 cells was significantly reduced by 1 mM ITF2357 as well as 1 mM ATRA. ITF2357 0.1 mM had no effect, but significantly reduced cell growth when combined with ATRA. Finally, cell growth was suppressed by the combination of 1 mM ITF2357 with ATRA. IC 50 values in NB4 cells, as calculated after 48 h treatment with ITF2357 or SAHA (graph not reported), were 0.75 and 1 mM, respectively. ITF2357 0.1 mM, which induced significant apoptosis in Kasumi-1 cells (Figure 2b ), was ineffective on HL60, THP1 or NB4 cells, while 1 mM increased apoptosis, in HL60 and THP1 in particular (Figure 4c ), although its effect was markedly lower than in Kasumi-1 cells. The treatment with 1 mM ITF2357 or 1 mM ATRA increased the percentage of apoptotic NB4 cells only slightly, whereas the combined treatment resulted in an additive effect. Therefore, a concentration of ITF2357 1 log higher is necessary to reduce viable cell number or induce apoptosis in AML1/ETO-negative cells.
Effects of ITF2357 on U937-A/E and primary AML cells
To confirm the specificity of low doses of ITF2357 for AML1/ETO-positive cells, we evaluated its effects in AML1/ETO-inducible U937-A/E-9/14/18 cells (Fliegauf et al., 2004; Figure 5a ). The increase of H4 acetylation in response to ITF2357 was comparable in AML1/ETO expressing and non-expressing cells (Figure 5b ). Figure 5c shows an increase of basal apoptosis following induction of AML1/ETO expression, as previously reported (Lu et al., 2006) . Treatment of AML1/ETO expressing, but not non-expressing, cells with 0.1 mM ITF2357 determined a significant increase of the percentage of apoptotic cells with respect to that of untreated controls. On the other hand, treatment with 1 mM ITF2357 determined similar effects in AML1/ETOexpressing and non-expressing cells, with no significant differences depending on the presence of AML1/ETO (Figure 5c ). The action of 0.1 mM ITF2357, as it was apparently exclusive for AML1/ETO-expressing cells, seemed, exactly for this reason, to be 'synergistic' with the apoptotic effects of AML1/ETO expression itself, observed also in Kasumi-1 cells (Gozzini et al., 2003) . Thus, these data confirmed that AML1/ETO expression renders cells very sensitive to low-dose ITF2357.
Primary blasts from an AML1/ETO-positive FAB-M2 AML (#1) treated with 0.1 mM ITF2357 underwent a marked induction of acetylation and apoptosis, as evidenced by pro-caspase 3 decrease and the corresponding appearance of caspase 3 fragments at 96 h (Figure 5d ). By contrast, blasts from AML1/ETO-negative FAB-M2 AML (#2 and #3) did not undergo apoptosis following ITF2357 treatment, although H4 was re-acetylated.
Effects of ITF2357 on chromatin remodelling in Kasumi-1 cells The effects of ITF2357 on the intracellular localization of proteins involved in epigenetic remodelling, such as p300 and DNMT1, were evaluated in Kasumi-1 cells by confocal microscopy (Figure 6a ). ITF2357 0.1 mM determined a massive increase of H4 acetylation (not shown), as already shown. Untreated cells showed a diffuse cellular distribution of p300 and a both nuclear and cytosolic localization of DNMT1. Administration of 0.1 mM ITF2357 induced nuclear increase of p300 and an exclusively cytosolic distribution of DNMT1.
All the above observations are sound confirmation of what we previously showed in terms of de-repression of gene transcription and removal of cell maturation blockage by HDACi in CBF-positive leukaemias (Gozzini et al., 2003) . It has been recently demonstrated that AML1/ETO recruits directly to the repressor complex both DNMT1 and HDAC1, which are thereby physically associated to the promoter region of AML1 targets, like the IL3 gene (Liu et al., 2005) . To assess whether ITF2357-induced histone acetylation occurred at the promoter sites of IL3 gene, which is silenced in AML1/ ETO-positive cells, chromatin immunoprecipitation assays were carried out in Kasumi-1 cells (Figure 6b ). IL3 promoter is characterized by the presence of two binding sites for AML1 and AML1/ETO placed at À192 bp (TGTGGT) and À105 bp (TGTGGG) from the start site of transcription. Our primers were designed to amplify a region including both binding sites. Kasumi-1 cells were treated for 6 h with 0.1 mM ITF2357, because histone acetylation peaked at this time (Figure 1b) . We then determined H4 acetylation and p300 recruitment at the IL3 promoter. Concomitantly, HDAC1, DNMT1 and, remarkably, AML1/ETO itself dissociated from the IL3 promoter. The dissociation of the repressor complex, which resulted in H4 acetylation and recruitment of p300 on the IL3 promoter, was not sufficient to determine the re-expression of IL3 gene (not shown). This is consistent with the fact that 0.1 mM ITF2357 for 24 h was unable to modify the methylation status of the seven CpG islands surrounding the IL3 promoter (not shown). Moreover, we found that the CpG island methylation of several other gene promoters (E-cadherin, p15, p73, DAPK), not controlled by AML1 or AML1/ETO, was unaffected by 0.1 mM ITF2357 after 6 or 24 h (Figure 6c ).
Discussion
Recently, HDACi have become the subject of intense research, addressed to synthesize and/or identify drugs effective in inducing acetylation, devoid of toxicity and In this paper, we evaluated the anti-leukaemic activity of ITF2357, an orally bioavailable HDACi currently in Phase I and II studies for several autoimmune disorders and haematological neoplasia. ITF2357 is not selective for individual HDAC subclasses, being active on class I and II HDAC (Leoni et al., 2005) . In long-term toxicity studies, ITF2357 has been found well tolerated by several experimental animal species (Italfarmaco archive data, available upon request). In our hands, in Kasumi-1, AML1/ETO-inducible U937-A/E-9/14/18, HL60, THP-1 and NB4 cell lines as well as primary AML cells, the acetylating activity of ITF2357 was extremely marked, with a clear dose-response correlation, H3 and H4 acetylation being detectable already at 0.1 mM. In Kasumi-1 cells, the time-response curve indicated an extremely rapid (peak at 6 h) induction of acetylation by ITF2357. Such a rapid acetylating effect is typical of hydroxamate derivatives, as opposed to short-chain fatty acids, and may account for the observed early effects of the drug. ITF2357-induced acetylation was partially reverted at 24 h, but when cultures were refed with ITF2357 at 24 h intervals, so as to mimic a clinical scheduling, histone acetylation was stably maintained at maximum levels throughout the experiment. In comparison to ITF2357, equimolar amounts of SAHA, induced a quantitatively weaker acetylation, although with the same kinetics. However, we cannot exclude that the weak acetylating effect of SAHA results in significant changes at specific gene loci. In summary, on the basis of our observations and data available in the literature, ITF2357 appears to be a very potent HDACi. 
Selectivity of low-dose ITF2357 in AML subtypes V Barbetti et al
In addition to histone acetylation, HDACi are known to determine block of progression into the S-phase of cell cycle, growth arrest and apoptosis, thereby being active on all AML cells, independently of the presence of specific molecular abnormalities. These effects, widely reported in literature, have been obtained using high concentrations of HDACi, which most probably provoke profound and generalized alterations of protein acetylation. Indeed, HDAC have multiple non-histone targets and may induce apoptosis via acetylation of transcription factors such as E2F-1 (Tan et al., 2006) . Furthermore, secondary epigenetic mechanisms may mediate lethality induced by HDACi, including reactive oxygen species generation, NFkB activation, disruption of G2 and mitotic checkpoints, activation of JNK and inactivation of ERK1/2, upregulation of proapoptotic genes and downregulation of antiapoptotic genes Rahmani et al., 2005) . On the other hand, in the experiments reported here, a low dose of ITF2357 (0.1 mM), which induces significant histone acetylation in all cells tested, succeeded in leading to apoptosis of AML1/ETO-positive cells only: Kasumi-1, AML1/ ETO-inducible U937 and AML1/ETO-positive primary cells. However, in keeping with the studies mentioned above, we also found that ITF2357 induced cell death in all the AML1/ETO-negative AML cells tested, but only at a concentration one log higher. Although the latter result seem to indicate that acetylation and apoptosis induced by ITF2357 are distinctly elicited phenomena, we showed that apoptosis induced by low-dose ITF2357 is linked to histone acetylation and that this link is most probably a direct consequence of AML1/ETO expression. We may therefore speculate that the anti-leukaemic activity of HDACi on AML1/ETO-positive cells is determined by mere 'epigenetic' mechanisms, leading to apoptosis. At support of this concept, we previously showed that CBF-leukaemias could be driven to terminal granulocytic maturation by HDACi (butyrate derivatives) as single drug treatment, whereas non-CBFleukaemias were not liable to mature, although histone acetylation was restored in both cases (Gozzini et al., 2003) . On the contrary, in AML1/ETO-negative cells, HDACi drive additional proapoptotic effects which are achieved at higher concentrations. We found that in NB4 cells, where PML/RARa recruits HDACs to the DNA repressor complex, ITF2357 induces apoptosis only when used at the higher dose, but its combination with ATRA results in a more than additive effect. This is clearly due to the key role of ATRA in removing this fusion protein from DNA (Raelson et al., 1996) .
In Kasumi-1 cells treated with 0.1 mM ITF2357, both caspases 9 and 8 were activated, and at different time points. This suggests that multiple apoptotic pathways are triggered by ITF2357, in keeping with recent findings which showed that the proapoptotic activity of ITF2357 is determined via both TRAIL-dependent and -independent pathways (Pathil et al., 2006) . Concurrently with apoptosis, AML1/ETO protein degradation was also induced in Kasumi-1 cells treated with 0.1 mM ITF2357. We demonstrated that this degradation was determined by caspase activation, well in keeping with what recently observed in Kasumi-1 cells exposed to diterpenoids (Wang et al., 2007) .
To investigate the molecular reasons of the apparently enhanced sensitivity of AML1/ETO-leukaemias to ITF2357, we evaluated the effects of HDACi treatment on the stability of the DNA/DNMT/HDAC1/AML1/ ETO complex. ATRA treatment, for instance, has been shown to release HDAC3 from the NCoR complex bound to PML-RARa (Atsumi et al., 2006) and determine hypomethylation of the RAR2a promoter (Altucci et al., 2005; Fazi et al., 2005) . We studied the intracellular distribution of acetylated H4, DNMT1 and p300. Upon ITF2357 treatment, H4 appeared acetylated and, in parallel, DNMT1 was dislocated to cytoplasm, whereas p300 moved from cytoplasm to nucleus, confirming the modulation of both the nuclear corepressor and co-activator complexes with subsequent reactivation of the transcriptional machinery by ITF2357. We consider extremely relevant that ITF2357 at the peak of histone acetylation provoked the release of HDAC1, and also of DNMT1 and AML1/ETO from the AML1-controlled IL3 gene promoter. In parallel, the IL3 gene promoter itself was enriched with p300 and acetylated H4. This observation indicates the direct or mediated binding of DNMT1 to the AML1/ETO/ HDAC1 complex, as already shown (Liu et al., 2005 . Our observation appears fundamental in view of the fact that the disruption of the AML1/ETO/ co-repressor complex implies a specific and direct action of ITF2357 on the leukaemogenic oncoprotein. The rapid release from DNA of AML1/ETO is followed, much later, by its degradation.
The concomitant release, following ITF2357 treatment, of DNMT1 and HDAC1 from the site of an AML1-controlled gene promoter prompted us to verify whether the promoter of IL3, but also those of several other hypermethylated genes, could revert their hypermethylation in ITF2357-treated AML1/ETO-positive cells. This was not the case for any of the genes tested. Neither IL3, nor p15ink4b, E-cadherin, p73 or DAPK gene promoters were demethylated by ITF2357. This may result from the fact that hypermethylation, once determined, is a relatively stable phenomenon. Although DNA methylation and histone acetylation are strictly connected and may modulate each other, DNA methylation is evidently predominant. Indeed, in our hands IL3 was not re-expressed. The practical aspect of this observation is that HDACi and DNMTi should in fact be used in combination in clinical trials.
In conclusion, this work indicates that ITF2357, a novel HDAC inhibitor of the family of hydroxamic acid, endowed with oral bioavailability, scarce toxicity and already in Phase I/II clinical trials is highly effective in restoring histone acetylation, inducing apoptosis and inhibiting cell proliferation in human AML. Such inhibition occurs selectively at low doses in AML1/ ETO-positive leukaemias and is paralleled by disruption and delocalization of the DNA-bound oncogeneco-repressor complex, responsible for the acquisition of the leukaemic phenotype in the AML1/ETO-positive cells.
Materials and methods
Cells and culture conditions
Kasumi-1 cells (an AML1/ETO-positive cell line derived from a human AML; Asou et al., 1991) , the human myelocytic leukaemia HL-60, the human myeloid monocytic leukaemia THP-1, the human promyelocytic leukaemia NB4 and the AML1/ETO-inducible promonocytic leukaemia U937-A/E-9/ 14/18 cells were plated at 3 Â 10 5 cells per ml in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 4 mM glutamine, 50 U ml À1 penicillin and 50 mg ml À1 streptomycin, at 37 1C in a humidified atmosphere containing 5% CO 2 . For the induction of AML1/ETO expression in U937-A/E-9/14/18 cells, 5 mM ponasterone A (Sigma, Milano, Italy) was added to the medium and western blot was performed to confirm AML1/ETO expression. The inducible U937 cell line model of AML1/ETO expression was established based on an ecdysoneinducible model as previously described (Fliegauf et al., 2004) . Mononucleated cells were obtained after informed consent from peripheral blood of de novo AML patients and density gradient centrifugation. Blasts were more than 95%, as morphologically determined, in the samples cultured. All the experiments were performed by incubation in the presence or the absence of different doses (as indicated) of ITF2357 (diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalene-2-methyl] ammonium chloride monohydrate; Italfarmaco S.p.A., Milano, Italy; WHO patented US006034096A), SAHA (Italfarmaco S.p.A., Milano, Italy), z-VAD-FMK (P-416; Biomol International, Milano, Italy), Bortezomib or ATRA (Roche, Milano, Italy).
Cell viability and apoptosis
Cell viability was evaluated and quantified by cell counting following trypan blue exclusion. To quantify apoptosis, cells were subjected to centrifugation and resuspended in 100 ml of 1 Â binding buffer (HEPES-buffered saline solution with 2.5 mM CaCl 2 ). PhycoErythrin(PE)-labelled Annexin-V (Roche Diagnostics) and propidium iodide (PI) were added, and cells were incubated for 15 min in the dark at room temperature (RT). After the addition of 400 ml of 1 Â binding buffer and agitation, flow cytometry was performed using a FACSscan (Beckton & Dickinson, San Jose`, CA, USA). Annexin-V þ /PIÀ cells were defined 'early apoptotic' and annexin-V þ /PI þ cells 'late apoptotic'. Total apoptosis was calculated by the sum of all annexin-V þ cells.
Cell lysis and western blotting
Cells were washed once with ice-cold phosphate-buffered saline (PBS) and solubilized by incubating for 10 min at 95 1C in Laemmli buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol, 0.005% blue bromphenol, 2% sodium dodecyl sulphate (SDS)). Lysates were clarified by centrifugation (20 000 g; 10 min, RT). Protein concentration in the supernatants was determined, and 30 mg aliquots of each sample were boiled for 10 min, in the presence of 100 mM 2-mercaptoethanol. Proteins were separated by SDS-PAGE in a 9-15% polyacrylamide gel and transferred onto polyvinylidene fluoride (PVDF) membranes (Hybond-ECL; Amersham Biosciences, Munich, Germany) by electroblotting. Membranes were incubated in PBS containing 0.1% Tween 20 and 1% bovine serum albumin (BSA; T-PBS/1%BSA; 3-5 h, RT), and then in a 1:1000 dilution of a primary antibody in the same buffer (6-18 h at 4 1C). Secondary antibodies, horseradish peroxidase conjugated, were anti-rabbit (A 6154; Sigma), anti-mouse (A 4416; Sigma) or anti-goat IgG (sc-2768; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Antibody-coated protein bands were visualized by ECL chemiluminescence detection (Amersham Biosciences). To check equal loading of sample or reprobe with different antibodies, membranes were incubated in stripping buffer (62.5 mM Tris-HCl pH 6.7, 2% SDS, 100 mM 2-mercaptoethanol; 30 min, 50 1C) and then extensively washed with T-PBS.
Immunofluorescence
Immunocytochemistry was performed according to manufacturer's instructions (Cell Signaling, Danvers, MA, USA), as summarized here below. After cytospin preparations on glass coverslips, cells were washed once with PBS and fixed with 4% formaldehyde in PBS (10 min, RT) and permeabilized by a 5 min incubation in PBS containing 0.2% Triton X-100. After three washes in PBS, cell protein binding sites were saturated by incubating with 10% horse serum in PBS/1%BSA (45 min, RT). Cells were washed once in PBS and incubated (overnight, 4 1C) in PBS/1%BSA supplemented with a 1:1000 dilution of a specific antibody. Cells were washed three times with PBS and immunocomplexes revealed with 1:500 dilution of anti-rabbit Cy3-labelled secondary antibodies (AP182C; Chemicon, Temecula, CA, USA) or anti-mouse Cy2-labelled secondary antibody (AP124J; Chemicon). Cells were washed once in PBS and incubated with the Hoechst nuclear dye diluted 1:2000 in PBS for 10 min at 37 1C. Following two washes in PBS, the coverslips were mounted with propyl-thiogallate on glass slides and cells observed with a confocal inverted microscope Nikon Eclipse TE2000, equipped with a Nikon S Fluor 60 Â immersion oil lens and a violet diode laser V-LD408 nm, a Ar488 nm argon laser and a He-Ne543 helium neon laser. The C1 software was used for acquisition and further image processing (image size setting) performed with Adobe Photoshop. The incubation with secondary antibody alone did not produce any significant fluorescence.
Chromatin immunoprecipitation assay
The ChIP assay was performed according to the manufacturer's recommendations (Upstate Biotechnology, Charlottesville, VA, USA), as summarized here below. 10 6 Kasumi-1 cells (3 Â 10 5 cells per ml) were treated with 1% formaldehyde for 10 min at 37 1C. Crosslinking was stopped by adding 0.125 M glycine. Cells were centrifuged for 5 min at 1300 r.p.m. at 4 1C and washed twice using ice-cold PBS containing protease inhibitors (1 mM phenylmethylsulphonyl fluoride (PMSF), 1 mg ml À1 aprotinin and 1 mg ml À1 pepstatin A). Cell pellet was lysed in 200 ml of lysis buffer (50 mM Tris-HCl, pH 8.1, 10 mM EDTA, 1% SDS, 1 mM PMSF, 1 mg ml À1 aprotinin and 1 mg ml À1 pepstatin A) for 10 min on ice and then sonicated (two pulses, 15 s each, power 5; Microson Misonix, Farmingdale, NY, USA) to generate DNA fragments of 500 bp on average. After centrifugation (13 000 r.p.m., 10 min, 4 1C), the supernatant was diluted 10-fold with ChIP dilution buffer (16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl, 1.2 mM EDTA, 0.01% SDS, 1.1% Triton X-100). A total of 4% of this sample was used as an indicator of chromatin content in each sample (input). The diluted suspensions were pre-cleared with 50 ml of sonicated salmon sperm DNA/protein G agarose (Upstate Biotechnology) for 1 h at 4 1C in agitation. Following centrifugation (1000 r.p.m., 1 min, 4 1C), 2 mg per sample of antibody was added to the supernatant and incubated overnight at 4 1C with agitation. Each sample was subjected in parallel to the same procedure without antibody (negative control). Antibody-protein-DNA complexes were collected by further incubation with 50 ml salmon sperm DNA/protein G agarose and centrifugation. After extensive washing, complexes were eluted with 500 ml elution buffer (0.1 M NaHCO3, 1% SDS). Following addition of 0.2 M NaCl, all samples, including input, were incubated at 65 1C for 4 h to revert crosslinking. After treatment with 10 mM RNase and digestion with 40 mM proteinase-K, DNA was extracted with a DNA purification system based on silica-membrane spin columns, according to the manufacturer's recommendations (Promega, Milano, Italy) and DNA eluted in 60 ml of water.
Methylation-specific PCR
To analyse hypermethylation of the promoters of several genes, genomic DNA was extracted from Kasumi-1 cells. Extracted DNA was modified by sodium bisulphite treatment (CpG genome DNA modification Kit; Intergen, NY, USA) according to the manufacturer's instructions. Purified DNA was mixed with 20 mM NaOH/90% ethanol and then precipitated with ethanol. DNA was then resuspended in 10-15 ml of 10 mM Tris/ 0.1 mM EDTA and stored at À20 1C until it was used for PCR.
PCR PCR was performed on a MasterCycler (Eppendorf, Milano, Italy) using GoTaq DNA Polymerase (Promega). The immunoprecipitated chromatin was analysed by PCR using these primer for the IL3 promoter: IL3-for, 5
0 -AGTCATG-GATGAATAATTACG-3 0 ; IL3-rev, 5 0 -TCCCGCCTTA-TATGTGC-3 0 . PCR was performed using following parameters: 94 
Antibodies
The following antibodies were used: rabbit polyclonal antiacetylated-H4 (ChIP-grade; 06-598; Upstate Biotechnology), anti-acetylated-H3 (06-599; Upstate Biotechnology), anti-H4 (07-108; Upstate Biotechnology), anti-cleaved caspase-9 (9501; Cell Signaling), anti-caspase-8 (sc-7890; Santa Cruz Biotechnology), anti-DNMT1 (ChIP-grade; ab5208; Abcam, Cambridge, UK), anti-DNMT1 (07-688; Upstate Biotechnology), anti-ERK1 (sc-93; Santa Cruz Biotechnology), anti-Hsp90a/b (sc-7947; Santa Cruz Biotechnology); mouse monoclonal anticaspase-3 (sc-7272; Santa Cruz Biotechnology), anti-p300 (ChIP-grade; 05-257; Upstate Biotechnology), anti-vinculin (v9131; Sigma); goat polyclonal anti-ETO (ChIP-grade; sc-9737; Santa Cruz Biotechnology), anti-HDAC1 (ChIP-grade; sc-6298; Santa Cruz Biotechnology), anti-pan-acetyl-lysine (sc-8649; Santa Cruz Biotechnology).
